In view of the additional ERBB2 mutation, which affects the RAS/RAF/MEK/ERK pathway 30, the tumor board recommended an off-label therapy with combined BRAF- and MEK-inhibition together with the intrathecal application of methotrexate. This evidence concerns the gene BRAF and neoplasm.